CRISPR Therapeutics GAAP EPS of -$2.40 misses by $0.19, revenue of $0.16M misses by $2.04M

Aug. 08, 2022 8:27 AM ETCRISPR Therapeutics AG (CRSP)By: Pranav Ghumatkar, SA News Editor3 Comments
  • CRISPR Therapeutics press release (NASDAQ:CRSP): Q2 GAAP EPS of -$2.40 misses by $0.19.
  • Revenue of $0.16M (-100.0% Y/Y) misses by $2.04M.
  • Cash, cash equivalents and marketable securities were $2,073.7 million as of June 30, 2022, compared to $2,379.1 million as of December 31, 2021. The decrease in cash of $305.4 million was primarily driven by cash used in operating activities to support ongoing research and development of the Company’s clinical and pre-clinical programs.

Recommended For You

Comments (3)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.